Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ele Ferrannini

Showing results (71-80 of 408) with videos related to

Pageof 41
Sort By:
Diabetes, Obesity & Metabolism|September 13, 2017
Insulin resistance and cardiovascular outcomes in the ORIGIN trialHertzel C Gerstein, Ele Ferrannini, Matthew C Riddle, et al.
Diabetologia|March 25, 2014
Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabeticAndrea Tura, Elza Muscelli, Amalia Gastaldelli, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 2, 2017
Insulin resistance and normal thyroid hormone levels: prospective study and metabolomic analysisEle Ferrannini, Giorgio Iervasi, Jeff Cobb, et al.
Growth Factors (Chur, Switzerland)|March 28, 2008
Effects of endothelin-1 on fibroblasts from type 2 diabetic patients: Possible role in wound healing and tissue repairAnna Solini, Eleonora Santini, Stephanie Madec, et al.
Diabetes Care|January 30, 2013
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetesEle Ferrannini, Stephan A Veltkamp, Ronald A Smulders, et al.
Microcirculation (New York, N.Y. : 1994)|December 17, 2008
Role of thromboxane A2 receptor on the effects of oxidized LDL on microvascular endothelium nitric oxide, endothelin-1, and IL-6 productionValter Lubrano, Simona Baldi, Ele Ferrannini, et al.
Metabolism: Clinical and Experimental|November 2, 2020
Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetesEleonora Grespan, Toni Giorgino, Andrea Natali, et al.
Diabetes Care|September 22, 2017
Diabetes Research and Care Through the AgesBernard Zinman, Jay S Skyler, Matthew C Riddle, et al.
Diabetologia|March 12, 2026
Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onsetCarmella Evans-Molina, Stephen E Gitelman, Andrea Mari, et al.
Chest|August 11, 2006
Prevalence of hypothyroidism and Graves disease in sarcoidosisAlessandro Antonelli, Piera Fazzi, Poupak Fallahi, et al.
Pageof 41

Showing results (71-80 of 408) with videos related to

Sort By:
Pageof 41
Diabetes, Obesity & Metabolism|September 13, 2017
Insulin resistance and cardiovascular outcomes in the ORIGIN trialHertzel C Gerstein, Ele Ferrannini, Matthew C Riddle, et al.
Diabetologia|March 25, 2014
Altered pattern of the incretin effect as assessed by modelling in individuals with glucose tolerance ranging from normal to diabeticAndrea Tura, Elza Muscelli, Amalia Gastaldelli, et al.
American Journal of Physiology. Endocrinology and Metabolism|March 2, 2017
Insulin resistance and normal thyroid hormone levels: prospective study and metabolomic analysisEle Ferrannini, Giorgio Iervasi, Jeff Cobb, et al.
Growth Factors (Chur, Switzerland)|March 28, 2008
Effects of endothelin-1 on fibroblasts from type 2 diabetic patients: Possible role in wound healing and tissue repairAnna Solini, Eleonora Santini, Stephanie Madec, et al.
Diabetes Care|January 30, 2013
Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetesEle Ferrannini, Stephan A Veltkamp, Ronald A Smulders, et al.
Microcirculation (New York, N.Y. : 1994)|December 17, 2008
Role of thromboxane A2 receptor on the effects of oxidized LDL on microvascular endothelium nitric oxide, endothelin-1, and IL-6 productionValter Lubrano, Simona Baldi, Ele Ferrannini, et al.
Metabolism: Clinical and Experimental|November 2, 2020
Different mechanisms of GIP and GLP-1 action explain their different therapeutic efficacy in type 2 diabetesEleonora Grespan, Toni Giorgino, Andrea Natali, et al.
Diabetes Care|September 22, 2017
Diabetes Research and Care Through the AgesBernard Zinman, Jay S Skyler, Matthew C Riddle, et al.
Diabetologia|March 12, 2026
Beta cell glucose sensitivity identifies clinical response to disease-modifying therapies initiated at stage 3 type 1 diabetes onsetCarmella Evans-Molina, Stephen E Gitelman, Andrea Mari, et al.
Chest|August 11, 2006
Prevalence of hypothyroidism and Graves disease in sarcoidosisAlessandro Antonelli, Piera Fazzi, Poupak Fallahi, et al.
Pageof 41